SOUTH CAROLINA – May 6, 2026 – Samay is a medtech company redefining respiratory diagnostics with Sylvee, the first wearable platform that uses patented Active Acoustic Resonance and AI to measure lung structure and function. Sylvee replaces the 40-minute, effort-dependent spirometry process with a 5-minute, passive test — enabling early detection of small airway disease (SAD) and COPD in primary care, continuous home monitoring, and high-frequency endpoint capture in pharma clinical trials.
Solutions
Sylvee sends acoustic signals into the chest cavity and reads the returning tissue resonance to detect airway obstruction, air trapping, and structural lung changes — replacing the 40-minute, effort-dependent spirometry with a 5-minute, low-effort test. It enables continuous respiratory monitoring at home, replacing routine site visits in decentralized trials while improving data density and patient retention.
Sylvee detects SAD (Sensitivity 88% vs. CT – AUC 0.93) and COPD (Sensitivity 87% vs. spirometry – AUC 0.89), enabling pharma partners to identify and stratify patients earlier for trial enrollment or targeted therapy, positioning it as a companion diagnostic for emerging biologics and inhaled therapies.
Strengths
- IP: 18 patents granted, 19 pending across 20+ countries.
- Pharma Revenue: $175K in active pilots; $10M contract in negotiation; $350K in new pilots.
- Strategic Partners: Chiesi (funded SAD algorithm pilot). SURA ($1M in-kind, two protocols, 2,600+ patients, 8 indications).
- Awards: 2024 MedTech Innovator Grand Prize. ATS 2025 Innovation Success Story. GoFest 2025 #1 Colombia Startup. StartCo 2026 #1 LatAm Startup.
- Funding: $5.8M raised — $2.9M non-dilutive (NIH, NSF, prizes).
- Current Round: $3M seed closing July 2026 (65% committed). ~50% of projected Series A valuation. Funds: RWE platform, Colombia launch, FDA Breakthrough Device Designation.
Meet the Founder
Maria Artunduaga | Founder + Chief Executive Officer